# Bristol-Myers Squibb Company (BMY) — Q4-2025 Earnings Results

**Report date:** 2026-02-05 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q4-2025

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 3.3%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.26 | N/A | +9.28% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook regarding their product performance. They emphasized the importance of their pipeline but did not provide specific guidance.

**Key quotes:**

> Management highlighted the strong performance in key therapeutic areas.

> They expressed confidence in the ongoing pipeline development.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a solid EPS beat, which contributed to a 3.3% increase in stock price. The positive surprise in EPS indicates stronger-than-expected profitability, although the lack of revenue data leaves some uncertainty. Investors may be encouraged by management's confidence in their product pipeline.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q4-2025_